Welcome to our dedicated page for Allogene Therapeutics news (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics stock.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies for cancer and autoimmune diseases. Leveraging the expertise of former Kite Pharma executives, Allogene aims to revolutionize cancer treatment with innovative off-the-shelf CAR T solutions. These therapies, derived from healthy donor cells, provide a scalable and readily available option, eliminating the lengthy and complex process of personalized cell therapy.
The company's portfolio includes 16 pre-clinical T cell therapy assets and UCART19, an allogeneic CAR T therapy in phase 1 development for acute lymphoblastic leukemia (ALL). Notable core programs target various malignancies such as lymphoma, leukemia, solid tumors, and autoimmune diseases. Among its leading investigational products is cemacabtagene ansegedleucel (cema-cel), currently undergoing pivotal phase 2 ALPHA3 trials for large B-cell lymphoma (LBCL) and phase 1 trials for relapsed/refractory chronic lymphocytic leukemia (CLL). ALLO-316, aimed at renal cell carcinoma (RCC), and ALLO-329, targeting autoimmune diseases with Dagger® technology, further strengthen Allogene's robust pipeline.
Allogene collaborates with leading biotech firms like Foresight Diagnostics and Arbor Biotechnologies to enhance its clinical development capabilities. Recent achievements include strategic partnerships and a $15 million grant from the California Institute for Regenerative Medicine (CIRM) supporting the development of ALLO-316. Financially, Allogene reported a strong cash runway extending into 2026, with latest funding rounds ensuring continued support for its R&D initiatives.
Stay informed on Allogene's progress as it drives the future of allogeneic CAR T therapy, providing broader patient access and more efficient cancer treatment options.
Allogene Therapeutics announced promising initial results from its Phase 1 UNIVERSAL trial of ALLO-715, an anti-BCMA AlloCAR T therapy for relapsed/refractory multiple myeloma. The therapy demonstrated a 60% overall response rate (ORR) at the highest administered dose of 320M CAR+ cells, with all responding patients achieving minimal residual disease (MRD) negative status. Notably, there was no observed neurotoxicity or graft-vs-host disease (GvHD). Ongoing enrollment aims to optimize dosing and lymphodepletion, with further data to be presented at the upcoming ASH Annual Meeting.
Allogene Therapeutics (ALLO) provided a corporate update and reported Q3 2020 financial results, reflecting continued progress in developing its AlloCAR T therapies. The company ended Q3 with $1.0 billion in cash and expects to submit several Investigational New Drug applications, including for ALLO-316 and ALLO-715, by the end of 2020. Initial clinical data from the UNIVERSAL trial for ALLO-715 in multiple myeloma will be announced in Q4 2020. Full-year net losses are projected between $260 million and $280 million, including significant stock-based compensation.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) will announce its Q3 2020 financial results on November 4, 2020, prior to market opening. A conference call and audio webcast will follow at 5:30 AM PT / 8:30 AM ET. The company focuses on developing allogeneic CAR T cell therapies, aiming to provide readily available treatment options for cancer patients. A replay of the webcast will be available for 30 days on their website. The press release contains forward-looking statements about the company's future and the potential benefits of its therapies.
Allogene Therapeutics (Nasdaq: ALLO) has entered a five-year collaboration with The University of Texas MD Anderson Cancer Center to evaluate multiple AlloCAR T candidates targeting various tumors. This partnership aims to expedite the development of allogeneic CAR T therapies, leveraging MD Anderson's clinical trial expertise and Allogene's cell therapy knowledge. The collaboration will entail joint oversight of preclinical and clinical studies, with Allogene funding the initiative.
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotech firm, announced its participation in the Jefferies Virtual Cell Therapy Summit on October 6, 2020. The event is scheduled for 12:30 PM PT/3:30 PM ET and will focus on the development of allogeneic CAR T therapies for cancer. A live webcast will be available on the company's website, with a replay for 30 days. Allogene aims to provide 'off-the-shelf' CAR T therapies, enhancing patient access and scalability in treatment.
Allogene Therapeutics reported promising initial Phase 1 results from the ALLO-501 ALPHA trial, showcasing a 75% overall response rate and 44% complete response rate in CAR T naïve relapsed/refractory non-Hodgkin lymphoma patients. Ongoing trials for ALLO-501A and ALLO-715 are also being developed, with initial data expected in Q4 2020. The company reported a net loss of $61.0 million for Q2 2020, while ending the quarter with $1.1 billion in cash and equivalents, ensuring robust financial support for upcoming clinical trials.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) will announce its second quarter 2020 financial results on August 5, 2020, prior to market opening. A live audio webcast and conference call is scheduled for 5:30 AM PT/8:30 AM ET. The event will be accessible via the Company's website, where a replay will also be available for approximately 30 days. The press release emphasizes the company's focus on developing allogeneic CAR T therapies for cancer, aiming to provide accessible treatment options to patients.
Notch Therapeutics has appointed David Main as President and CEO, enhancing its leadership to drive the development of innovative, off-the-shelf T cell therapies from stem cells. Main brings over 30 years of biopharmaceutical experience, previously leading Aquinox Pharmaceuticals through successful phases of development and public listing. Notch's advanced Engineered Thymic Niche (ETN) technology aims to create universal T cell therapies, and the company is currently partnered with Allogene Therapeutics (NASDAQ: ALLO) to focus on CAR-targeted therapies for hematologic cancers.
Allogene Therapeutics (Nasdaq: ALLO) announced that Dr. Ton Schumacher, Principal Investigator at the Netherlands Cancer Institute and chair of its Scientific Advisory Board, received the prestigious Stevin Prize for his research in cancer immunotherapy. This award, worth 2.5 million euros, recognizes impactful scientific contributions and will fund further research into predicting T cell responses to cancer antigens. Dr. Schumacher's work is pivotal in advancing AlloCAR T™ therapies aimed at transforming cancer treatment. His recognition enhances Allogene's reputation and leadership in the field.
Allogene Therapeutics (Nasdaq: ALLO) announced preclinical findings on DLL3-targeted AlloCAR T therapy for small cell lung cancer (SCLC) and its iTurboCAR technology at the AACR annual meeting. These studies provide scientific support for the AlloCAR and TurboCAR platforms. Findings indicated engineered T cells targeting DLL3 exhibited long-term efficacy without causing brain damage. Additionally, the iTurboCAR technology allows controlled cytokine activation, enhancing CAR T cell potency. Both innovations underline Allogene's commitment to advancing allogeneic cell therapies.
FAQ
What is the current stock price of Allogene Therapeutics (ALLO)?
What is the market cap of Allogene Therapeutics (ALLO)?
What is Allogene Therapeutics, Inc.?
What are Allogene's core products?
What is unique about Allogene's therapies?
Who are Allogene's key partners?
In which clinical trials is cema-cel involved?
What recent financial achievement did Allogene secure?
How does Allogene's financial outlook appear?
What is the focus of Allogene's ALLO-316 trial?
What is the Dagger® technology used in ALLO-329?
What is the goal of Allogene's therapies?
